Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Maze Therapeutics, Inc.NASDAQ: MAZE
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash declines year over year
Q1 FY2026 net change in cash of $9.52M fell 90.2% year over year, ahead of the -136.2% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -57.8% a year.
Context
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -90.2% holds above the trailing-twelve-month pace of -136.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (7.57M) USD
- Year-over-year change
- -104.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.57M) | -104.5% |
| FY2024 | 2024-12-31 | 167.65M | +336.5% |
| FY2023 | 2023-12-31 | (70.88M) | +29.6% |
| FY2022 | 2022-12-31 | (100.65M) | — |
Net Change in Cash vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -136.2% is the 7th highest of 8, against a peer median of -83.1%.
- Net change in cash amounts to 478.0% of revenue for MAZE, versus a peer median of 77.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | LTM Sep 2026 | $152.87M USD | -166.0% | — | 158.8% |
| LTM Mar 2026 | $95.61M USD | -136.2% | -57.8% | 478.0% | |
| LTM Jun 2026 | $33.26M USD | -90.9% | +27.2% | 3.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $15.71M USD | -119.6% | +70.2% | 152.3% |
| FY2025 | €14.17M EUR | -79.7% | +326.2% | 316.0% | |
| LTM Sep 2026 | $12.61M USD | -83.1% | — | 1.9% | |
| LTM Mar 2026 | $2.28M USD | +363.2% | +743.9% | — | |
| LTM Mar 2026 | $401K USD | +107.5% | -49.4% | 0.1% | |
| Peer median (excluding MAZE) | — | -83.1% | +70.2% | 77.8% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.